POLB and prostate carcinoma: Natamycin, an antibiotic/anti-fungal agent, has been shown to inhibit the strand displacement activity of Polβ (at 2–5 nM), and at higher (μM) concentrations inhibited both Polβ and LigI, and consequently reduced proliferation of androgen-depleted prostate cancer cell lines [64].